01:07 PM EST, 02/06/2025 (MT Newswires) -- Eli Lilly ( LLY ) reported in-line fourth-quarter sales on Thursday, while reiterating a 2025 revenue guidance that implies the top line will grow at the same pace as it did last year.

Revenue climbed to $13.53 billion for the three months ended Dec. 31 from $9.35 billion the year earlier and was in line with the average analyst estimate on FactSet. Adjusted earnings per share more than doubled to $5.32 from $2.49 year over year and beat the Street's $5.01 view.

Shares of Eli Lilly ( LLY ) jumped 4.5% in midday trade.

For 2025, the pharmaceutical giant continues to guide sales in the $58 billion to $61 billion range, matching the initial range it provided last month. The company expects adjusted EPS between $22.50 and $24. The consensus is for revenue of $58.77 billion and non-GAAP EPS of $22.77 in the ongoing year.

The revenue outlook implies year-over-year growth of about 32% at the midpoint, matching its 2024 sales growth rate. Sales in 2025 are expected to be driven by weight loss drug Zepbound and diabetes treatment Mounjaro, among others, the company said.

New indications for existing Eli Lilly ( LLY ) drugs, launches of Mounjaro in additional markets, and new medicines including metastatic breast cancer treatment imlunestrant are also expected to add to the top-line expansion in 2025, the company said. Eli Lilly ( LLY ) continues to "invest heavily in increasing manufacturing capacity," it wrote.

Growth in the fourth quarter was led by volume gains for Mounjaro and Zepbound. Mounjaro saw sales grow 60% year over year to $3.53 billion, while revenue of Zepbound in the US soared to $1.91 billion from $175.8 million. Zepbound launched in the US in November 2023.

Overall sales were partially offset by a 25% top-line decline for diabetes and cardiovascular disease treatment Trulicity amid "competitive dynamics" in the US. Consolidated US revenue jumped 40% to $9.03 billion, while sales outside the country were up 55% to $4.5 billion.

Price: 870.80, Change: +28.62, Percent Change: +3.40